Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Rationale and clinical data

Expert Review of Anticancer Therapy

Volumn 12, Issue 7, 2012, Pages 895-911

  De Bree, Eelco ^a   Helm, C William ^b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIPEC; hyperthermic intraperitoneal chemotherapy; intraperitoneal chemotherapy; ovarian cancer

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TOPOTECAN;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CELL HETEROGENEITY; CONSOLIDATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG STABILITY; DRUG THERAPY; DRUG TIMING; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; OVARY CANCER; PATIENT SELECTION; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; RISK BENEFIT ANALYSIS; SECOND LOOK SURGERY; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; THERMOSTABILITY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; OVARIAN NEOPLASMS; PATIENT SELECTION; PERITONEUM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84864594492     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.72     Document Type: Review

References (89)

1. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 17(6), 528-536 (2011). 1 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
3. McGuire WP III, Markman M. Primary ovarian cancer chemotherapy: Current standards of care. Br. J. Cancer 89(Suppl. 3), S3-S8 (2003).
4. Dedrick RL, Meyers CE, Bungay PM, DeVita PJ Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1-11 (1978).
5. Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol. Oncol. 100, 3-4 (2006).
6. Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments. J. Natl Cancer Inst. 98, 1655-1663 (2006).
7. Elit L, Oliver T, Covens A et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. A systemic review with metaanalysis. Cancer 109, 692-702 (2007).
8. De Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res. 169, 39-51 (2007).
9. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J. Am. Med. Assoc. 159, 1704-1707 (1955).
10. Flessner MF. The transport barrier in intraperitoneal therapy. Am. J. Physiol. Renal Physiol. 288, F433-F442 (2005).
11. van Der Speeten. K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 15, 216-224 (2009).
12. De Lima Vazquez V, Stuart OA, Mohamed F, Sugarbaker PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Cancer Chemother. Pharmacol. 52, 108-112 (2003).
13. De Bree E, Witkamp AJ, Zoetmulder FAN. Intraperitoneal chemotherapy for colorectal cancer. J. Surg. Oncol. 79, 46-61 (2002).
14. De Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: FFOM laboratory bench to bedside. Recent Results Cancer Res. 169, 53-73 (2007).
15. Sugarbaker PH. Peritonectomy procedures. Surg. Oncol. Clin. N. Am. 12, 703-727 (2003).
16. Ibeanu OA, Bristow RE. Predicting the outcome of cytoreductive surgery for advanced ovarian cancer. A review. Int. J. Gynecol. Cancer 20, S1-S11 (2007).
17. Harter P, Hagmann M, Lieck HJ et al. Surgery for recurrent ovarian cancer: Role of peritoneal carcinomatosis: Exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann. Surg. Oncol. 16, 1324-1330 (2009).
18. Harter P, Sehoul J, Reuss A et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int. J. Gynecol. Cancer 21, 289-295 (2011).
19. Eisenkop SM, Spiros NM, Lin WC. 'Optimal' cytoreduction for advanced epithelial ovarian cancer: A commentary. Gynecol. Oncol. 103, 329-335 (2006).
20. Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 14, 683-694 (2009).
21. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIC or IV ovarian cancer. N. Engl. J. Med. 363, 943-953 (2010).
22. De Bree E, Romanos J, Michalakis J et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res. 23, 3019-3028 (2003).
23. Garafallo A, Valle M, Garcia J, Sugarbaker PH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur. J. Surg. Oncol. 32, 682-685 (2006).
24. Witkamp AJ, De Bree E, van Goethem AR, Zoetmulder FAN. Rationale and technique of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat. Rev. 27, 365-374 (2001).
25. Hofstra LS, Bos AME, De Vries EGE et al. Kinetic modelling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol. Oncol. 85, 517-523 (2002).
26. Markman M, Kulp B, Peterson G et al. Second-line therapy of ovarian cancer with paclitaxel administered by both the intravenous and intraperitoneal routes: RATIONALE and case reports. Gynecol. Oncol. 86, 95-98 (2002).
27. Rothenberg ML, Liu PY, Braly PS et al. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: RESULTS from an Intergroup Phase II trial. J. Clin. Oncol. 21, 1313-1319 (2003).
28. Kyrgiou M, Salanti G, Pavlidis N et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: A meta-analysis of multiple treatments. J. Natl Cancer Inst. 98, 1655-1663 (2006).
29. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 150-155 (1996).
30. Markman M, Bundy B, Alberts DS et al. Phase III study of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19, 1001-1007 (2001).
31. De Bree E, Theodoropoulos PA, Rosing H et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside. Cancer Treat. Rev. 32, 471-482 (2006).
32. De Bree E, Rosing H, Michalakis J et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur. J. Surg. Oncol. 32, 666-670 (2006).
33. Armstrong DK, Bundy BN, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43 (2006).
34. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev. 25, CD005340 (2006).
35. Helm CW. Ports and complications for intraperitoneal therapy. Br. J. Obstet. Gynecol. 119, 150-159 (2012).
36. Walker JL, Armstrong DK, Huang HQ et al. Intraperitoneal catheter outcomes in a Phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol. Oncol. 100, 27-32 (2006).
37. Piccart MJ, Floquet A, Scarfone G et al. Intraperitoneal cisplatin versus no further treatment: 8 year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer 13(Suppl, 2), 196-203 (2003).
38. Alberts DS, Hannigan EV, Liu PY et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. Gynecol. Oncol. 100, 133-138 (2006).
39. Fujiwara K, Armstrong D, Morgan M et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int. J. Gynecol. Cancer 17, 1-20 (2007).
40. Takemoto M, Kuroda M, Urano M et al. The effect of various chemotherapeutic agents given at mild hyperthermia on different types of tumours. Int. J. Hyperthermia 19, 193-203 (2003).
41. van Ruth S, Verwaal VJ, Hart AA et al. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res. 23, 1501-1508 (2003).
42. Markman M. Intraperitoneal taxol. Cancer Treat. Res. 81, 1-5 (1996).
43. Rupniak HY, Whelan RD, Hill BT. Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int. J. Cancer 32, 7-12 (1983).
44. Michalakis J, Georgatos SD, De Bree E et al. Short term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long term inhibition of cell proliferation and cell death in vitro. Ann. Surg. Oncol. 14, 1220-1228 (2007).
45. Michalakis J, Georgatos SD, Romanos J et al. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells. Cancer Chemother. Pharmacol. 56, 615-622 (2005).
46. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg. Oncol. Clin. N. Am. 12, 755-769 (2003).
47. Markman M. Intraperitoneal chemotherapy in the management of malignant disease. Expert Rev. Anticancer. Ther. 1, 142-148 (2001).
48. De Bree E, Rosing H, Filis D et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: A clinical and pharmacokinetic study. Ann. Surg. Oncol. 15, 1183-1192 (2008).
49. Bae JH, Lee JM, Ryu KS et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol. Oncol. 106, 193-200 (2007).
50. Piso P, Glockzin G, von Breitenbuch P et al. Patient selection for a curative approach to carcinomatosis. Cancer J. 15, 236-242 (2009).
51. Verwaal V, van Ruth S, De Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21, 3737-3743 (2003).
52. De Bree E, Witkamp AJ, Zoetmulder FA. Peroperative hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer. Eur. J. Surg. Oncol. 26, 630-631 (2000).
53. Yan TD, Black D, Sugarbaker PH et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann. Surg. Oncol. 14, 2701-2713 (2007).
54. Deraco M, Raspagliesi F, Kusamura S. Management of peritoneal surface component of ovarian cancer. Surg. Oncol. Clin. N. Am. 12, 561-583 (2003).
55. Chi DS, Eisenhauer EL, Zivanovic O et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 114, 26-31 (2009).
56. Bijelic L. Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann. Oncol. 18, 1943-1950 (2007).
57. Chua T.C. Robertson G. Liauw W. Farrell R. Yan T.D. Morris D.L. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: Systemic review of current results J. Cancer Res. Clin. Oncol. 135, 1637-1645 (2009).
58. Helm CW, Richard SD, Pan J et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. First report of the HYPER-O Registry. Int. J. Gynecol. Cancer 20, 61-69 (2010).
59. Berreder J, Glehen O, Habre J et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: A multiinstitutional study of 246 patients. J. Clin. Oncol. 27(15S) (2009) (Abstract 5542).
60. Rufian S, Munoz-Casares FC, Briceno J et al. Radical surgery- peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J. Surg. Oncol. 94, 316-324 (2006).
61. Deraco M, Kusamura S, Virzi S et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: A multi-institutional Phase-II trial. Gynecol. Oncol. 122, 215-220 (2011).
62. Lim MC, Kang S, Choi J et al. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a Phase II study. Ann. Surg. Oncol. 16, 993-1000 (2009).
63. Cascales Campos PA, Gil Martinez J, Galindo Fernandez PJ, Gil Gomez E, Martinez Frutos IM, Parrilla Paricio P. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. Eur. J. Surg. Oncol. 37, 543-548 (2011).
64. Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM. Cytoreductive surgery and modified heated intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer - 12 year single center experience. Eur. J. Surg. Oncol. 35, 1186-1191 (2009).
65. Roviello F, Pinto E, Corso G et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary and recurrent ovarian cancer. J. Surg. Oncol. 102, 663-670 (2010).
66. Carrabin N, Mithieux F, Meeus P et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull. Cancer 97, E23-E33 (2010).
67. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet. Gynecol. 93
68. Gori J, Castano R, Toziano M et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int. J. Gynecol. Cancer 15, 233-239 (2005).
69. Kim JH, Lee JM, Ryu KS et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J. Surg. Oncol. 101, 149-155 (2010).
70. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol. Oncol. 112, 265-274 (2009).
71. Rasaglieri F, Kusamura S, Campos Torres JC et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur. J. Surg. Oncol. 32, 671-675 (2006).
72. Ceelen WP, Van Nieuwebhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann. Surg. Oncol. doi:10.1245/s10434-009- 0878-6 (2009) (Epub ahead of print).
73. Fagotti A, Costantini B, Vizzielli G et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of outcome. Gynecol. Oncol. 122, 221-225 (2011).
74. Munoz-Casares FC, Rufian S, Rubio MJ et al. The role of hyperthermic intraoperative chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin. Transl. Oncol. 11, 753-759 (2009).
75. Ryu KS, Kim JH, Ko HS et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol. Oncol. 94, 325-332 (2004).
76. De Bree E, Tsiftsis DD, Melissas J. Hyperthermic intraperitoneal chemotherapy (HIPEC) in optimally cytoreduced peritoneal carcinomatosis of gynecology origin: does it provide survival advantage? In: Cytoreductive Surgery in Gynaecologic Oncology: A Multidisciplinary Approach. Yidirim Y (Ed.). Transworld Research Network, Kerala, India, 73-100 (2010).
77. Helm CW, Bristow RE, Kusamura S et al. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J. Surg. Oncol. 98, 283-290 (2008).
78. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin for advanced ovarian cancer: A Phase 3, open-label, randomized controlled trial. Lancet 374, 1331-1338 (2009).
79. Kristensen G, Perren T, Qian W et al. Results of interim analysis of overall survival in the GCIG ICON7 Phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract LBA5006).
80. Vergote I, Tropé CG, Amant F et al. Neoaduvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943-953 (2010).
81. Chua TC, Liauw W, Robertson G, Morris DL. Establishing evidence for change in ovarian cancer surgery - proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. Gynecol. Oncol. 115, 166-168 (2009).
82. Di Giorgio A, Naticchioni E, Biacchi D et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113, 315-325 (2008).
83. Pomel C, Ferron G, Lorimier G et al. Hyperthemic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a Phase II prospective multicentre trial. CHIPOVAC study. Eur. J. Surg. Oncol. 36, 589-593 (2010).
84. Frenel JS, Leux C, Pouplin L et al. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. J. Surg. Oncol. 103, 10-16 (2011).
85. Piso P, Dahlke M-H, Loss M, Schlitt HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis. World J. Surg. Oncol. 2, 21-28 (2004).
86. Zanon C, Clara R, Chiappino I et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J. Surg. 28, 1040-1045 (2004).
87. Helm CW, Randall-Whitis L, Martin RS 3rd et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol. Oncol. 105, 90-96 (2007).
88. Cotte E, Glehen O, Mohamed F et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistent and recurrent advanced epithelial ovarian cancer: Prospective study of 81 patients. World J. Surg. 31, 1813-1820 (2007).
89. Königsrainer I, Beckert S, Becker S et al. Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: Experience and lessons learned. Langenbeck Arch. Surg. 396, 1077-1081 (2011).